Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nanoparticle steroid spray could transform recovery after sinus surgery

NCT ID NCT07714525

Disease control Sponsor: Deraya University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This trial tests a new nanoparticle spray containing the steroid triamcinolone acetonide for people recovering from endoscopic sinus surgery. The spray is designed to deliver the drug directly to the nasal cavity to reduce inflammation and improve healing. Researchers compare it to standard saline irrigation in adults with chronic rhinosinusitis or nasal polyps. The goal is to see if the nanoparticle formulation leads to better recovery and fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
triamcinolone acetonide-loaded polymeric nanocapsules
What this could lead to
If it works, this could offer a more effective and safer way to deliver steroids after sinus surgery, reducing inflammation and improving healing with fewer side effects.
What could go wrong
This is a small, early-phase trial, so results may not be conclusive. The nanoparticle formulation may not work better than standard care, and there is a risk of corticosteroid-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Adults aged 18 to 60 years. * Patients scheduled to undergo one of the following procedures: * Functional endoscopic sinus surgery * Endoscopic turbinoplasty * Endoscopic septoplasty * Diagnosis of chronic rhinosinusitis and/or nasal polyps requiring surgical intervention. * Ability and willingness to provide written informed consent. * Ability and willingness to comply with study treatment and scheduled follow-up visits. Exclusion Criteria * Known hypersensitivity to triamcinolone acetonide. * Known hypersensitivity to any component of the polymeric nanocapsule formulation. * Systemic contraindication to corticosteroid therapy. * Active severe nasal or sinonasal infection at the time of enrollment or treatment. * Pregnancy or breastfeeding, if excluded in the approved protocol. * Uncontrolled diabetes mellitus, if corticosteroid exposure is considered clinically relevant. * Immunosuppression or use of immunosuppressive therapy. * Recent use of systemic or intranasal corticosteroids within the protocol-defined washout period. * Participation in another clinical trial. * Any medical or psychiatric condition that may interfere with informed consent, study treatment, or follow-up. * Inability to complete the required questionnaires or follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic rhinosinusitis (CRS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic rhinosinusitis nasal cavity polyp

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic rhinosinusitis (CRS) Nasal polyps Postoperative healing after endoscopic nasal surgery

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Deraya university, faculty of pharmacy

    RECRUITING

    Minya, Menia Governorate, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.